Edition:
India

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

48.40USD
17 Nov 2017
Change (% chg)

$0.65 (+1.36%)
Prev Close
$47.75
Open
$47.67
Day's High
$48.41
Day's Low
$47.65
Volume
324,941
Avg. Vol
311,995
52-wk High
$63.40
52-wk Low
$46.65

Select another date:

Thu, Nov 16 2017

BRIEF-Alkermes’ NDA for ARISTADA accepted for filing by U.S. FDA

* Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® accepted for filing by U.S. FDA

BRIEF-ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA, INVEGA SUSTENNA FOR SCHIZOPHRENIA

* ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA® AND INVEGA SUSTENNA® FOR THE TREATMENT OF SCHIZOPHRENIA

BRIEF-ALKERMES PLC REPORTS ‍Q3 GAAP LOSS PER SHARE OF $0.24

* ‍Q3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION​

BRIEF-Alkermes qtrly gaap loss per share $0.28

* Qtrly revenues increased 12% year-over-year to $218.8 million

BRIEF-Alkermes announces positive preliminary topline results

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients

* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients

Select another date: